Literature DB >> 18000201

Evaluation and treatment of chagas disease in the United States: a systematic review.

Caryn Bern1, Susan P Montgomery, Barbara L Herwaldt, Anis Rassi, Jose Antonio Marin-Neto, Roberto O Dantas, James H Maguire, Harry Acquatella, Carlos Morillo, Louis V Kirchhoff, Robert H Gilman, Pedro A Reyes, Roberto Salvatella, Anne C Moore.   

Abstract

CONTEXT: Because of population migration from endemic areas and newly instituted blood bank screening, US clinicians are likely to see an increasing number of patients with suspected or confirmed chronic Trypanosoma cruzi infection (Chagas disease).
OBJECTIVE: To examine the evidence base and provide practical recommendations for evaluation, counseling, and etiologic treatment of patients with chronic T cruzi infection. Evidence Acquisition Literature review conducted based on a systematic MEDLINE search for all available years through 2007; review of additional articles, reports, and book chapters; and input from experts in the field. EVIDENCE SYNTHESIS: The patient newly diagnosed with Chagas disease should undergo a medical history, physical examination, and resting 12-lead electrocardiogram (ECG) with a 30-second lead II rhythm strip. If this evaluation is normal, no further testing is indicated; history, physical examination, and ECG should be repeated annually. If findings suggest Chagas heart disease, a comprehensive cardiac evaluation, including 24-hour ambulatory ECG monitoring, echocardiography, and exercise testing, is recommended. If gastrointestinal tract symptoms are present, barium contrast studies should be performed. Antitrypanosomal treatment is recommended for all cases of acute and congenital Chagas disease, reactivated infection, and chronic T cruzi infection in individuals 18 years or younger. In adults aged 19 to 50 years without advanced heart disease, etiologic treatment may slow development and progression of cardiomyopathy and should generally be offered; treatment is considered optional for those older than 50 years. Individualized treatment decisions for adults should balance the potential benefit, prolonged course, and frequent adverse effects of the drugs. Strong consideration should be given to treatment of previously untreated patients with human immunodeficiency virus infection or those expecting to undergo organ transplantation.
CONCLUSIONS: Chagas disease presents an increasing challenge for clinicians in the United States. Despite gaps in the evidence base, current knowledge is sufficient to make practical recommendations to guide appropriate evaluation, management, and etiologic treatment of Chagas disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18000201     DOI: 10.1001/jama.298.18.2171

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  223 in total

Review 1.  Chagas heart disease: report on recent developments.

Authors:  Fabiana S Machado; Linda A Jelicks; Louis V Kirchhoff; Jamshid Shirani; Fnu Nagajyothi; Shankar Mukherjee; Randin Nelson; Christina M Coyle; David C Spray; Antonio C Campos de Carvalho; Fangxia Guan; Cibele M Prado; Michael P Lisanti; Louis M Weiss; Susan P Montgomery; Herbert B Tanowitz
Journal:  Cardiol Rev       Date:  2012 Mar-Apr       Impact factor: 2.644

Review 2.  Cardiac involvement with parasitic infections.

Authors:  Alicia Hidron; Nicholas Vogenthaler; José I Santos-Preciado; Alfonso J Rodriguez-Morales; Carlos Franco-Paredes; Anis Rassi
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

3.  Crystal structures of Trypanosoma cruzi UDP-galactopyranose mutase implicate flexibility of the histidine loop in enzyme activation.

Authors:  Richa Dhatwalia; Harkewal Singh; Michelle Oppenheimer; Pablo Sobrado; John J Tanner
Journal:  Biochemistry       Date:  2012-06-05       Impact factor: 3.162

Review 4.  Chagas disease and transfusion medicine: a perspective from non-endemic countries.

Authors:  Andrea Angheben; Lucia Boix; Dora Buonfrate; Federico Gobbi; Zeno Bisoffi; Simonetta Pupella; Giorgio Gandini; Giuseppe Aprili
Journal:  Blood Transfus       Date:  2015-10       Impact factor: 3.443

5.  Does Progressive Introduction of Benznidazole Reduce the Chance of Adverse Events in the Treatment of Chagas Disease?

Authors:  Irene Losada Galván; Olaya Madrid Pascual; Juan María Herrero-Martínez; Ana Pérez-Ayala; Manuel Lizasoain Hernández
Journal:  Am J Trop Med Hyg       Date:  2019-06       Impact factor: 2.345

Review 6.  Management of Esophageal Dysphagia in Chagas Disease.

Authors:  Roberto Oliveira Dantas
Journal:  Dysphagia       Date:  2021-04-14       Impact factor: 3.438

7.  Trypanosoma cruzi: synergistic cytotoxicity of multiple amphipathic anti-microbial peptides to T. cruzi and potential bacterial hosts.

Authors:  Annabeth Fieck; Ivy Hurwitz; Angray S Kang; Ravi Durvasula
Journal:  Exp Parasitol       Date:  2010-03-03       Impact factor: 2.011

8.  Chagas Cardiomyopathy in New Orleans and the Southeastern United States.

Authors:  Robert C Hsu; Joshua Burak; Sumit Tiwari; Chayan Chakraborti; Gary E Sander
Journal:  Ochsner J       Date:  2016

Review 9.  Diagnosis and management of Chagas disease and cardiomyopathy.

Authors:  Antonio L Ribeiro; Maria P Nunes; Mauro M Teixeira; Manoel O C Rocha
Journal:  Nat Rev Cardiol       Date:  2012-07-31       Impact factor: 32.419

Review 10.  Infectious Diseases of Poverty in Children: A Tale of Two Worlds.

Authors:  Caitlin Hansen; Elijah Paintsil
Journal:  Pediatr Clin North Am       Date:  2016-02       Impact factor: 3.278

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.